drugset / Trial / NCT02050802

Study to Assess the Effect of Macitentan on the Electrocardiogram (ECG) in Healthy Male and Female Subjects

NCT02050802

Phase 1 Completed 64 enrolled Actelion
RandomizedCrossoverTriple-blindOther

Summary

The study is intended to demonstrate that macitentan does not have an effect on cardiac repolarization exceeding the threshold of regulatory concern after repeated administration of daily oral doses of 10 and 30 mg to healthy male and female subjects.

Timeline

Start
2011-08
Primary completion
2011-11
Completion
2011-11

Drugs

EvaluationDrugModalityDoseRoute
Subject Macitentan Other / unclassified 10 mg Oral
Subject Macitentan Other / unclassified 30 mg Oral
Subject Moxifloxacin Small molecule 400 mg

Indications

No indication recorded.